title: Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia.
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA, USA jennifer_brown@dfci.harvard.edu.
authors.forename: Jennifer R
authors.initials: JR
authors.lastname: Brown
authors.affiliation: Horizon Oncology Center, Lafayette, IN, USA.
authors.forename: Wael A
authors.initials: WA
authors.lastname: Harb
authors.affiliation: Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, OH, USA.
authors.forename: Brian T
authors.initials: BT
authors.lastname: Hill
authors.affiliation: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
authors.forename: Janice
authors.initials: J
authors.lastname: Gabrilove
authors.affiliation: Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR, USA.
authors.forename: Jeff P
authors.initials: JP
authors.lastname: Sharman
authors.affiliation: Clearview Cancer Institute, Huntsville, AL, USA.
authors.forename: Marshall T
authors.initials: MT
authors.lastname: Schreeder
authors.affiliation: Hematology/Oncology, University of Rochester Medical Center, Rochester, NY, USA.
authors.forename: Paul M
authors.initials: PM
authors.lastname: Barr
authors.affiliation: Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA.
authors.forename: James M
authors.initials: JM
authors.lastname: Foran
authors.affiliation: University of Arizona Cancer Center, Tucson, AZ, USA.
authors.forename: Thomas P
authors.initials: TP
authors.lastname: Miller
authors.affiliation: Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX, USA.
authors.forename: Jan A
authors.initials: JA
authors.lastname: Burger
authors.affiliation: University of Texas Health Science Center at San Antonio, CTRC Institute for Drug Development, TX, USA.
authors.forename: Kevin R
authors.initials: KR
authors.lastname: Kelly
authors.affiliation: The West Clinic, University of Tennessee Health Sciences Center, ACORN Research, LLC, Memphis, TN, USA.
authors.forename: Daruka
authors.initials: D
authors.lastname: Mahadevan
authors.affiliation: Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
authors.forename: Shuo
authors.initials: S
authors.lastname: Ma
authors.affiliation: Department of Translational Medicine, Celgene Corporation, San Francisco, CA, USA.
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Translational Medicine, Celgene Corporation, San Francisco, CA, USA.
authors.forename: Daniel W
authors.initials: DW
authors.lastname: Pierce
authors.affiliation: Celgene Corporation, Summit, NJ, USA.
authors.forename: Evelyn
authors.initials: E
authors.lastname: Barnett
authors.affiliation: Celgene Corporation, Summit, NJ, USA.
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Marine
authors.affiliation: Celgene Corporation, Summit, NJ, USA.
authors.forename: Monika
authors.initials: M
authors.lastname: Miranda
authors.affiliation: Celgene Corporation, Berkeley Heights, NJ, USA.
authors.forename: Ada
authors.initials: A
authors.lastname: Azaryan
authors.affiliation: Celgene Corporation, Berkeley Heights, NJ, USA.
authors.forename: Xujie
authors.initials: X
authors.lastname: Yu
authors.affiliation: Celgene Corporation, Summit, NJ, USA.
authors.forename: Pilar
authors.initials: P
authors.lastname: Nava-Parada
authors.affiliation: Celgene Corporation, Summit, NJ, USA.
authors.forename: Jay
authors.initials: J
authors.lastname: Mei
authors.affiliation: University of California, San Diego, Moores Cancer Center, La Jolla, CA, USA.
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Kipps
mesh_terms: D000178:Acrylamides / Q000008:administration & dosage* / Q000009:adverse effects; D000328:Adult; D000077329:Agammaglobulinaemia Tyrosine Kinase; D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000201:enzymology / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D012008:Recurrence; D015996:Survival Rate
chemical_list: D000178:Acrylamides; D011743:Pyrimidines; C583568:spebrutinib; D011505:Protein-Tyrosine Kinases; D000077329:Agammaglobulinaemia Tyrosine Kinase; C000625949:BTK protein, human
keywords: BTK inhibitors; CC-292; chronic lymphocytic leukemia; refractory; relapsed; single-agent; small lymphocytic lymphoma